The Week in Blood Pressure & Wearables — September 11-18, 2026
Medicare just put a price on technology-supported chronic care, and it did not wait for the wearable industry to sort out what "cuffless blood pressure" actually means. Both stories matter to anyone building remote patient monitoring for hypertension, and they are more connected than they look.
This week's roundup pulls from six Google Alert categories (blood pressure, wearable health technology, heart rate variability, chronic care management, telemedicine, and digital health) plus Blythe Karow's "The Device Files" newsletter. It was a busy week for Medicare policy and consumer wearables, and a quiet one for heart rate variability and chronic care management outside of the Medicare news itself, both of which produced mostly noise once you strip out consumer fitness roundups and unrelated disease-management coverage.
Policy & Regulation
CMS expands the ACCESS model, and puts real dollars behind chronic care technology
The Centers for Medicare & Medicaid Services this week expanded its Advancing Chronic Care with Effective, Scalable Solutions (ACCESS) model to cover four new condition tracks: heart failure, COPD, tobacco cessation, and substance use disorder, on top of the model's existing scope. CMS's own announcement frames this as new Medicare options for people managing some of the country's most common and costly chronic conditions.
The payment structure is the part worth sitting with, and it is more specific than a single headline number suggests. CMS's own payment methodology pays a fixed amount per beneficiary for each 12-month Care Period, and that amount varies by clinical track and by whether the beneficiary is new to the track (an "Initial Period," the richer rate) or already established in ongoing management (a "Follow-On Period," roughly half). The Cardio-Kidney-Metabolic track pays $420 for an Initial Period and $210 for Follow-On; the newly added Early Cardio-Kidney-Metabolic track pays $360 and $180; behavioral health runs $180 and $90. CMS disburses that monthly but caps in-year payment at half the total, holding the rest until a semi-annual reconciliation checks whether at least half of an organization's aligned beneficiaries actually hit their required outcome targets. Miss that bar badly and the withheld half can be cut in full, but never the whole payment, so this is not literally all-or-nothing. It is still a meaningfully different posture than fee-for-service billing for remote monitoring. It rewards results, not volume, which changes who wants to participate and how they build.
Two things happened almost immediately. First, AliveCor launched KardiaACCESS, a Medicare-covered program built specifically to improve blood pressure, diabetes, and heart health outcomes under the ACCESS framework. Second, Counsel Health brought Oura into the CMS ACCESS model as part of a deepening partnership, an early and explicit example of a wearable maker plugging directly into a Medicare payment model rather than staying purely consumer-facing.
Not everyone is enrolling. STAT News reported that some of the most prominent chronic disease technology companies, including Omada, Sword Health, and Hinge Health, chose not to participate. That split is worth watching. It usually means either the outcomes bar is set high enough to scare off companies without the clinical infrastructure to hit it, or those companies have reimbursement models elsewhere that they consider more favorable. Both explanations point to the same conclusion: this model will reward companies that can prove clinical impact, not just usage.
A skeptical counterweight: does virtual chronic care actually work?
The same week Medicare expanded its bet on technology-enabled chronic care, the Peterson Health Technology Institute published an assessment finding limited impact from virtual chronic kidney disease management solutions. PHTI's review found no consistent evidence that current virtual CKD programs slow disease progression or lower costs, and the finding has prompted pushback from the industry it studied.
I do not think these two stories contradict each other. I think they are the same conversation from opposite ends. Medicare is willing to pay for technology-supported chronic care, but it is tying real money to outcomes precisely because the sector has a track record of promising more than it has proven. PHTI's report reminds us that a "digital health company enrolled in a Medicare model" and a "digital health company that demonstrably improves patient outcomes" are not automatically the same claim.
RPM reimbursement uncertainty is not going away
A parallel thread this week: states are putting real budget behind remote patient monitoring even as providers and telehealth advocacy groups, including ATA Action, raised concerns about a proposed CMS reimbursement change that could affect how RPM and remote therapeutic monitoring get billed going forward. Separately, the Trump administration announced nearly $17 million to help rural health systems adopt emerging technologies, explicitly naming telemedicine and remote patient monitoring as priorities for getting care closer to home.
Put together: the money is moving toward RPM and chronic care technology from multiple directions this week, state grants, a rural technology fund, and an expanded national model, while the actual reimbursement rules underneath it all are still being negotiated. If you build or sell RPM technology, this is not the week to assume the ground is settled.
The FDA is watching hypertension management tools directly, too
Outside the ACCESS model, the FDA selected four digital health companies for its TEMPO pilot, a Medicare technology-enabled meaningful outcomes program. Two of the four selected companies focus on behavioral health; a third, Cadence Solutions, is offering a digital tool specifically for hypertension management. That is a small detail in a busy regulatory week, but it is a direct signal that hypertension is one of the conditions federal pilots are actively testing technology against, not an afterthought behind diabetes or heart failure.
Devices & Wearables: the deep dive
Circular adds cuffless blood pressure estimation to its Ring 2, and the framing matters
Circular announced blood pressure monitoring for its Circular Ring 2, using a combination of ECG and PPG (photoplethysmography) sensors to let users estimate their systolic and diastolic blood pressure. I want to be precise about the word "estimate" there, because it is doing real work. Based on what has been published about this feature, it is a PPG- and ECG-based estimation- the cuffless, optical family of blood pressure technology- not a direct oscillometric measurement and not something described as FDA-cleared for diagnostic use. If Circular publishes a clearance or a validation study against a reference cuff, that would be worth following up on, but nothing in this week's coverage claims that yet.
This is exactly the space where a company can quietly blur the line between "wellness feature that estimates a trend" and "medical device that measures blood pressure," and it is worth naming plainly every time it comes up. Estimating blood pressure from pulse wave characteristics captured at the wrist or finger is a real and active area of research. So far, it is also meaningfully less accurate and less validated across diverse patients than a properly calibrated cuff, which is why regulators have generally kept these features on the wellness side of the line rather than the medical side.
Huawei Watch D3: worth revisiting, correctly this time
The Huawei Watch D3 also generated coverage again this week, including a Notebookcheck deep dive on its ECG technology. For the record, and because getting this wrong once already cost this column credibility it should not have spent: the Watch D3 measures blood pressure using a miniaturized inflatable airbag cuff built into the watch band, evaluated with the oscillometric method. That is the same underlying principle as a traditional arm or wrist cuff, engineered into a much smaller form factor. It is not a cuffless, optical measurement, and it should never be described that way. The distinction between an inflatable cuff shrunk down to watch size and a truly cuffless, PPG-derived estimate is not a technicality. It is the difference between a device built on decades of validated cuff-based measurement science and a device that has to prove a comparatively new estimation approach works as well.
Apple's Series 12 and Ultra 4 bring a bigger health push, without a blood pressure claim
Apple's Series 12 and Ultra 4 launched this week with what Apple calls its most accurate heart-rate sensing system in a wearable, a new "Between Beats" feature, higher-frequency heart rate and heart rate variability sampling (as often as every five seconds instead of every two minutes), and a new Readiness score. Coverage ranged from The Verge's review to ZDNet testing the heart-rate claims against a chest strap to Apple's own technical explanation of the sensing system. None of this week's coverage describes a blood pressure feature for the new Apple Watch models, so I am not going to speculate about a mechanism where none has been claimed. What is notable is how much sensor and software investment is going into heart rate and readiness metrics generally, since that is the same underlying signal-quality question any future cuffless blood pressure feature would depend on.
The regulatory groundwork behind every wearable ECG feature you have ever used
Blythe Karow's newsletter, The Device Files, used WHOOP's new metal Meridian band to make a bigger point that is directly relevant to how Cardiowell thinks about hardware changes on a cleared device. WHOOP received FDA clearance for its ECG feature (atrial fibrillation, normal sinus rhythm, low and high heart rate detection) in April 2025, as a software-only medical device intended for use with the WHOOP strap. Karow's reporting explains that when a company changes the physical hardware- a new metal band, a different clasp, a different coating- it has to evaluate under FDA guidance whether that change could affect the safety or effectiveness of the previously cleared measurement. If it could, it requires a new submission. If not, the change gets documented internally. That single requirement is why you will never see a wearable company market new hardware finishes as "also unlocks the ECG feature" without first confirming the new material performs the same as what was actually tested and cleared.
Clinical & Research
A cluster of research this week reinforces something Cardiowell has always built around: how you measure blood pressure changes what you get, and behavior-based interventions are showing real, measurable effect on control.
A Johns Hopkins clinical trial found that an unsupported arm during a blood pressure reading overestimated systolic blood pressure by an average of 6.5 mmHg, enough on its own to shift some people from a normal reading into a hypertension diagnosis. That is a stark reminder that measurement technique is not a footnote in hypertension care. It is a variable large enough to change a diagnosis.
Separately, a real-world study covered by News-Medical found that an AI-driven health coaching app, combined with home blood pressure monitoring and behavioral incentives, helped patients achieve meaningfully better blood pressure control. A related real-world study in the Journal of General Internal Medicine, covered by Bioengineer.org, found similar results from a gamified AI-powered app. Two independent studies pointing in the same direction in one week are worth noting: the combination of accurate home monitoring plus consistent behavioral engagement is where the real blood pressure control gains are showing up, not from any single clever sensor.
New research also complicates a long-held assumption about hypertension and sex. Cardiovascular Business reported that pulse pressure, the gap between systolic and diastolic readings, behaves differently in women than in men earlier in life than previously assumed, a finding with implications for how early hypertension risk gets assessed by sex. And a JAMA Network Open study covered by News-Medical examined blood pressure responses during extreme heat across 4.2 million community health center visits, finding varied and not fully predictable blood pressure responses to heat exposure, especially for people who already have hypertension.
Also worth a glance
The FDA granted Nutromics a Breakthrough Device Designation for its wearable vancomycin monitor, a reminder that wearable sensing is expanding well beyond cardiovascular metrics into therapeutic drug monitoring. And Cebreo Medical received a CE Mark for NeuroBuds, an in-ear, medical-grade EEG wearable, which is worth flagging for anyone tracking how far wearable regulatory clearances are reaching beyond the wrist. Separately, Oura is facing a lawsuit centered on sleep-tracking accuracy claims, a case worth watching regardless of outcome because it puts a real legal test behind the gap between marketing language and validated accuracy that this column keeps coming back to.
Where this leaves us
Every story this week points at the same seam: Medicare is now willing to pay real, outcomes-linked money for chronic care technology, wearable companies are racing to plug into that money, and the accuracy and validation standards underneath the sensors doing the measuring have not caught up to the pace of that money moving. Cardiowell went through FDA 510(k) clearance for our BT107 device; we don’t want to build a hypertension RPM business on a measurement standard under scrutiny. That is a slower, more expensive path than shipping a wellness feature and calling it close enough. Watching Medicare start to reward outcomes over volume, and watching PHTI ask hard questions about whether virtual chronic care actually works, tells me the industry is heading toward the same standard we already chose to build to. The companies that got there early will have an easier next few years than the ones still hoping nobody checks.
References
CMS expands ACCESS model to cover more chronic conditions. Healthcare IT News.
AliveCor Launches KardiaACCESS: A Medicare-Covered Program Built to Improve Blood Pressure, Diabetes and Heart Health. Markets Insider (Business Insider).
Counsel Health taps Oura to join CMS ACCESS model. Fierce Healthcare.
Medicare to expand pilot that pays for technology to manage chronic diseases. STAT News.
PHTI report finds limited impact from virtual kidney care solutions, prompting industry pushback. Fierce Healthcare.
States are betting millions on remote monitoring. Providers, tech groups say proposed changes could hurt access. Fierce Healthcare.
Trump Administration Announces Nearly $17 Million to Adopt Emerging Healthcare Technologies. CMS.
FDA Selects Four Digital Health Companies For TEMPO Pilot; Two Focus On Behavioral Health. Open Minds.
Circular Adds Blood Pressure Monitoring To Circular Ring 2 Using ECG And PPG Sensors. Pulse 2.0.
Huawei Watch D3: ECG technology in detail — limitations, benefits, and background. Notebookcheck.
The Apple Watch Series 12 is the start of a new wearable era. The Verge.
I tested the Apple Watch Series 12 heart-rate claims against my gold-standard Polar strap. ZDNET.
Apple explains the science behind its 'most accurate heart sensing in a wearable' claim. Wareable.
WHOOP's New Band Is Effortless Elegance. The Engineering Behind It Is Anything But. The Device Files (Blythe Karow).
Your Arm Position Changes Your Blood Pressure Reading. Here's How To Get It Right. StudyFinds.
AI-driven health app helps patients achieve better blood pressure control. News-Medical.
AI-Powered Gamified App Linked to Sharper Blood Pressure Drops in Real-World Study. Bioengineer.org.
New data challenge long-held assumption about high blood pressure in women. Cardiovascular Business.
What happens to blood pressure during extreme heat? A 4.2 million-visit study offers a clue. News-Medical.
Nutromics receives FDA Breakthrough Device Designation. Business Wire.
Cebreo Medical Receives CE Mark for NeuroBuds, a Discreet In-Ear, Medical-Grade EEG Wearable. Rutland Herald.
Oura Lawsuit Focuses on Questions About Wearable Sleep Accuracy. Telehealth.org.